CN1602962A - 口蹄疫全病毒基因工程疫苗及其制备方法 - Google Patents
口蹄疫全病毒基因工程疫苗及其制备方法 Download PDFInfo
- Publication number
- CN1602962A CN1602962A CNA2004100403899A CN200410040389A CN1602962A CN 1602962 A CN1602962 A CN 1602962A CN A2004100403899 A CNA2004100403899 A CN A2004100403899A CN 200410040389 A CN200410040389 A CN 200410040389A CN 1602962 A CN1602962 A CN 1602962A
- Authority
- CN
- China
- Prior art keywords
- foot
- mouth disease
- phage
- soc
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 70
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims description 13
- 241000700605 Viruses Species 0.000 title abstract description 18
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims abstract description 90
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 claims abstract description 74
- 231100000614 poison Toxicity 0.000 claims abstract description 19
- 239000002245 particle Substances 0.000 claims abstract description 15
- 238000010353 genetic engineering Methods 0.000 claims abstract description 14
- 239000000523 sample Substances 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 6
- 241000588724 Escherichia coli Species 0.000 claims abstract description 4
- 241000710914 Totivirus Species 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 15
- 108010008038 Synthetic Vaccines Proteins 0.000 claims description 14
- 229940124551 recombinant vaccine Drugs 0.000 claims description 14
- 239000002574 poison Substances 0.000 claims description 11
- 108020004414 DNA Proteins 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 208000030194 mouth disease Diseases 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 7
- 239000013612 plasmid Substances 0.000 claims description 7
- 230000003321 amplification Effects 0.000 claims description 6
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 6
- 238000002823 phage display Methods 0.000 claims description 6
- 238000003757 reverse transcription PCR Methods 0.000 claims description 6
- 102100031974 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Human genes 0.000 claims description 5
- 101000703754 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 claims description 5
- 101710140501 Sulfate adenylyltransferase subunit 2 1 Proteins 0.000 claims description 5
- 101710173681 Sulfate adenylyltransferase subunit 2 2 Proteins 0.000 claims description 5
- 102100030100 Sulfate anion transporter 1 Human genes 0.000 claims description 5
- 101710144481 Sulfate anion transporter 1 Proteins 0.000 claims description 5
- BTWUORFYKAZQHW-UHFFFAOYSA-L disodium;2-hydroxy-3-[4-[4-[(2-hydroxy-3-sulfonatopropyl)amino]-3-methylphenyl]-2-methylanilino]propane-1-sulfonate Chemical compound [Na+].[Na+].C1=C(NCC(O)CS([O-])(=O)=O)C(C)=CC(C=2C=C(C)C(NCC(O)CS([O-])(=O)=O)=CC=2)=C1 BTWUORFYKAZQHW-UHFFFAOYSA-L 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 102000053602 DNA Human genes 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 238000009395 breeding Methods 0.000 claims description 3
- 230000001488 breeding effect Effects 0.000 claims description 3
- 239000012531 culture fluid Substances 0.000 claims description 3
- 238000013461 design Methods 0.000 claims description 3
- 238000001085 differential centrifugation Methods 0.000 claims description 3
- 230000006801 homologous recombination Effects 0.000 claims description 3
- 238000002744 homologous recombination Methods 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 238000002123 RNA extraction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000630 rising effect Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 abstract description 7
- 208000015181 infectious disease Diseases 0.000 abstract description 7
- 210000002966 serum Anatomy 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 230000009849 deactivation Effects 0.000 abstract description 3
- 230000003612 virological effect Effects 0.000 abstract description 3
- 239000008187 granular material Substances 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 2
- 230000007096 poisonous effect Effects 0.000 abstract 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 abstract 1
- 239000000284 extract Substances 0.000 abstract 1
- 239000002853 nucleic acid probe Substances 0.000 abstract 1
- 229960004854 viral vaccine Drugs 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 13
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 229940031551 inactivated vaccine Drugs 0.000 description 6
- 239000003440 toxic substance Substances 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 229940031626 subunit vaccine Drugs 0.000 description 5
- 241001494479 Pecora Species 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 206010004053 Bacterial toxaemia Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 101710175243 Major antigen Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241001493546 Suina Species 0.000 description 2
- 208000013222 Toxemia Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 1
- 206010059410 Faecaluria Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101150104425 T4 gene Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000021217 seedling development Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
组别 | 成年鼠受试数 | 乳鼠受试数 | 死亡数 | 存活数 | 保护率 |
全病毒疫苗株T4-FMDV-P1口服 | 10 | 30 | 0 | 30 | 100% |
全病毒疫苗株T4-FMDV-P1注射 | 10 | 30 | 0 | 30 | 100% |
参考:亚单位疫苗株T4-FMDV-F3口服 | 5 | 15 | 7 | 8 | 53% |
参考:亚单位疫苗株T4-FMDV-F3注射 | 5 | 15 | 4 | 11 | 73% |
不免疫动物空白对照 | 5 | 15 | 15 | 0 | 0% |
全病毒疫苗株T4-FMDV-P1注射 | 猪2头 | 0 | 2 | ||
注:猪2头仅为初试,正寻找经费进行大批量试验 | |||||
(以上试验在云南保山口蹄疫疫苗厂进行) |
组别 | 幼鼠受试数 | 死亡数 | 存活数 | 保护率 |
灭活苗阳性对照 | 6 | 0 | 6 | 100% |
全病毒疫苗株T4-FMDV-P1口服 | 9 | 0 | 9 | 100% |
全病毒疫苗株T4-FMDV-P1注射 | 5 | 0 | 5 | 100% |
参考:亚单位疫苗株T4-FMDV-F3口服 | 12 | 4 | 8 | 66% |
参考:亚单位疫苗株T4-FMDV-F3注射 | 12 | 3 | 9 | 75% |
T4噬菌体本底对照 | 7 | 7 | 0 | 0% |
不免疫动物空白对照 | 5 | 15 | 0 | 0% |
(以上试验在三达公司委托华南农大兽医学院进行) |
Claims (4)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2004100403899A CN1602962A (zh) | 2004-08-04 | 2004-08-04 | 口蹄疫全病毒基因工程疫苗及其制备方法 |
US11/188,236 US20060029615A1 (en) | 2004-08-04 | 2005-07-22 | Novel recombinant T4 phage particle and uses thereof |
PCT/US2005/026360 WO2006028591A2 (en) | 2004-08-04 | 2005-07-23 | Novel recombinant t4 phage particles and uses thereof |
CA002511314A CA2511314A1 (en) | 2004-08-04 | 2005-08-05 | Novel recombinant t4 phage particle and uses thereof |
US11/656,792 US20080299082A1 (en) | 2004-08-04 | 2007-01-23 | Novel recombinant T4 phage particle containing HIV, H. pylori or cancer antigens and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2004100403899A CN1602962A (zh) | 2004-08-04 | 2004-08-04 | 口蹄疫全病毒基因工程疫苗及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1602962A true CN1602962A (zh) | 2005-04-06 |
Family
ID=34664645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004100403899A Pending CN1602962A (zh) | 2004-08-04 | 2004-08-04 | 口蹄疫全病毒基因工程疫苗及其制备方法 |
Country Status (2)
Country | Link |
---|---|
US (1) | US20060029615A1 (zh) |
CN (1) | CN1602962A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101491671A (zh) * | 2008-12-05 | 2009-07-29 | 中国科学院海洋研究所 | 一种交叉保护疫苗及其构建方法 |
CN103074359A (zh) * | 2013-01-29 | 2013-05-01 | 连云港脂立方生物医药研究所有限公司 | 使用细胞内同步表达法在t4噬菌体表面展示外源蛋白大分子的方法 |
CN103933581A (zh) * | 2014-05-04 | 2014-07-23 | 贵州大学 | 一种基于csf-fmd二联基因工程疫苗的制备方法 |
CN110128509A (zh) * | 2019-05-17 | 2019-08-16 | 石河子大学 | 一种噬菌体展示口蹄疫颗粒、制备方法及疫苗 |
CN112481221A (zh) * | 2019-09-10 | 2021-03-12 | 宁波大学 | 迟钝爱德华氏菌高效裂解性噬菌体vB_EtaM-IME523及其应用 |
RU2809219C1 (ru) * | 2023-05-11 | 2023-12-07 | Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГТУ "ВНИИЗЖ") | Вакцина против ящура генотипа SAT-1/NWZ культуральная инактивированная сорбированная |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4875497B2 (ja) * | 2003-12-17 | 2012-02-15 | ザ カソリック ユニヴァーシティ オブ アメリカ | バクテリオファージナノ粒子を含む方法および組成物 |
US9163262B2 (en) | 2003-12-17 | 2015-10-20 | The Catholic University Of America | In vitro and in vivo delivery of genes and proteins using the bacteriophage T4 DNA packaging machine |
JP5902160B2 (ja) * | 2010-07-08 | 2016-04-13 | ユナイテッド・バイオメディカル・インコーポレーテッドUnited Biomedical Incorporated | デザイナーペプチドベースのpcv2ワクチン |
CN108646013A (zh) * | 2018-05-17 | 2018-10-12 | 贵州都匀市黔昌畜牧发展有限责任公司 | 一种猪疾病的监测方法 |
CN110878320A (zh) * | 2018-09-05 | 2020-03-13 | 湖北微生元生物科技有限公司 | 使用t4噬菌体展示技术高效表达超敏蛋白的方法 |
CN110885847A (zh) * | 2018-09-05 | 2020-03-17 | 湖北微生元生物科技有限公司 | 使用t4噬菌体展示技术高效表达超敏蛋白的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5559018A (en) * | 1983-09-13 | 1996-09-24 | Mattson; Thomas L. | Inviable phages, their production and DNA thereof |
US6057098A (en) * | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
US6555310B1 (en) * | 1997-04-04 | 2003-04-29 | Biosite Diagnostics, Inc. | Polyclonal libraries |
JP2002514919A (ja) * | 1997-04-04 | 2002-05-21 | バイオサイト ダイアグノスティックス,インコーポレイテッド | 多価ライブラリーおよびポリクローナルライブラリー |
US7041441B1 (en) * | 1997-04-11 | 2006-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Phage display of intact domains at high copy number |
US6500611B2 (en) * | 2000-08-17 | 2002-12-31 | Thomas L. Mattson | Inviable virus particles as scaffolds for constructing flexible detection systems |
US6777239B2 (en) * | 2001-04-17 | 2004-08-17 | Xenoport, Inc. | Epitope-captured antibody display |
-
2004
- 2004-08-04 CN CNA2004100403899A patent/CN1602962A/zh active Pending
-
2005
- 2005-07-22 US US11/188,236 patent/US20060029615A1/en not_active Abandoned
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101491671A (zh) * | 2008-12-05 | 2009-07-29 | 中国科学院海洋研究所 | 一种交叉保护疫苗及其构建方法 |
CN101491671B (zh) * | 2008-12-05 | 2012-11-21 | 中国科学院海洋研究所 | 一种交叉保护疫苗及其构建方法 |
CN103074359A (zh) * | 2013-01-29 | 2013-05-01 | 连云港脂立方生物医药研究所有限公司 | 使用细胞内同步表达法在t4噬菌体表面展示外源蛋白大分子的方法 |
CN103074359B (zh) * | 2013-01-29 | 2014-10-29 | 连云港脂立方生物医药研究所有限公司 | 使用细胞内同步表达法在t4噬菌体表面展示外源蛋白大分子的方法 |
CN103933581A (zh) * | 2014-05-04 | 2014-07-23 | 贵州大学 | 一种基于csf-fmd二联基因工程疫苗的制备方法 |
CN110128509A (zh) * | 2019-05-17 | 2019-08-16 | 石河子大学 | 一种噬菌体展示口蹄疫颗粒、制备方法及疫苗 |
CN110128509B (zh) * | 2019-05-17 | 2023-09-12 | 石河子大学 | 一种噬菌体展示口蹄疫颗粒、制备方法及疫苗 |
CN112481221A (zh) * | 2019-09-10 | 2021-03-12 | 宁波大学 | 迟钝爱德华氏菌高效裂解性噬菌体vB_EtaM-IME523及其应用 |
RU2809219C1 (ru) * | 2023-05-11 | 2023-12-07 | Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГТУ "ВНИИЗЖ") | Вакцина против ящура генотипа SAT-1/NWZ культуральная инактивированная сорбированная |
RU2815541C1 (ru) * | 2023-05-11 | 2024-03-18 | Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") | Вакцина против ящура генотипа SAT-2/IV культуральная инактивированная сорбированная |
Also Published As
Publication number | Publication date |
---|---|
US20060029615A1 (en) | 2006-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101514334B (zh) | 鸡传染性支气管炎病毒弱毒疫苗株及其应用 | |
CN106636012B (zh) | 一种猪盖他病毒毒株、疫苗组合物及其制备方法和应用 | |
Li et al. | Isolation and evolutionary analyses of gout-associated goose astrovirus causing disease in experimentally infected chickens | |
CN104513827A (zh) | 一种猪流行性腹泻病毒株、其弱毒疫苗株及应用 | |
Atkins et al. | Characterization of an outbreak of astroviral diarrhea in a group of cheetahs (Acinonyx jubatus) | |
CN104498441B (zh) | 鸭甲肝病毒iii型弱毒株及由其制备的活疫苗和应用 | |
CN101508978B (zh) | 一株鸡源h9n2禽流感病毒毒株的分离鉴定和纯化方法及其应用 | |
CN1602962A (zh) | 口蹄疫全病毒基因工程疫苗及其制备方法 | |
Abolnik et al. | Characterization of pigeon paramyxoviruses (Newcastle disease virus) isolated in South Africa from 2001 to 2006 | |
CN102221618B (zh) | 猪瘟兔化弱毒标记疫苗毒株的构建及疫苗的制备方法 | |
CN108085416A (zh) | 一种禽肿瘤病三重荧光pcr检测试剂盒及其检测方法 | |
CN101508977A (zh) | 一种鸡源h9n2禽流感病毒毒株的分离鉴定和纯化方法及其应用 | |
CN103725651A (zh) | 一株猪流行性腹泻病毒及其应用 | |
US10894081B2 (en) | Recombinant bivalent inactivated vaccine against foot-and-mouth disease virus, preparation method and use thereof | |
Park et al. | Molecular detection and characterization of unclassified bovine enteric caliciviruses in South Korea | |
CN109402065A (zh) | 一种番鸭c亚型禽偏肺病毒弱毒株及其制备和应用 | |
CN110551694B (zh) | 塞尼卡谷病毒svv/ch/zz/2016 | |
CN112522212B (zh) | 一种猪流行性腹泻病毒株及其灭活疫苗与干扰素联合免疫方法 | |
CN111057682A (zh) | 一株禽源h9n2亚型禽流感毒株分离鉴定及应用 | |
CN109055320A (zh) | 一株传染性支气管炎病毒分离株及在疫苗制备中的应用 | |
Kapoor et al. | Infectious bursal disease: Overview | |
CN106916832A (zh) | O型口蹄疫病毒重组核酸、重组疫苗株及其制备方法和应用 | |
CN102965345A (zh) | 猪细小病毒、疫苗组合物及其应用 | |
CN109504664B (zh) | 一种ⅲ型鸭甲型肝炎病毒鸡胚化弱毒株及其应用 | |
CN112094821B (zh) | 一种o型口蹄疫病毒株及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: DALI SANDA BIOLOGY SCIENCE CO., LTD. Effective date: 20050304 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050304 Address after: Wang Qi Ying Yunnan city of Kunming Province in 14 million unit 8 Building 4 floor, No. 1 Applicant after: Ren Zhaojun Address before: Wang Qi Ying Yunnan city of Kunming Province in 14 million unit 8 Building 4 floor, No. 1 Applicant before: Ren Zhaojun Co-applicant before: Dali Sanda Biotechnology Co., Ltd. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |